Trial · NCT03779334
Results by group17
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 17 of 17
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Percentage of Participants With Two Copies of the Survival Motor Neuron (SMN) 2 Gene (Excluding the Known SMN2 Gene Modifier Mutation c.859G>C) and Baseline Compound Muscle Action Potential (CMAP) >=1.5 Millivolt (mV) Who Are Sitting Without Support | 2 SMN2 Copies, Risdiplam | 80.0 | 90% Confidence Interval 34.26 to 98.98 | percentage of participants | |
| Percentage of Participants With Two Copies of the SMN2 Gene Sitting Without Support for 5 Seconds (Independent of the CMAP Value at Baseline). | 2 SMN2 Copies, Risdiplam | 87.5 | 90% Confidence Interval 52.93 to 99.36 | percentage of participants | |
| Change From Baseline Score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale at Month 12 | 2 SMN2 Copies, Risdiplam | Baseline | 46.50 | Full Range 35.0 to 52.0 | score on a scale |
| Change From Baseline Score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale at Month 12 | 3 SMN2 Copies, Risdiplam | Baseline | 55.00 | Full Range 44.0 to 62.0 | score on a scale |
| Change From Baseline Score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale at Month 12 | >/=4 SMN2 Copies, Risdiplam | Baseline | 50.00 | Full Range 44.0 to 52.0 | score on a scale |
| Change From Baseline Score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale at Month 12 | 2 SMN2 Copies, Risdiplam | Change from Baseline at Month 12 | 9.50 | Full Range -6.0 to 20.0 | score on a scale |
| Change From Baseline Score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale at Month 12 | 3 SMN2 Copies, Risdiplam | Change from Baseline at Month 12 | 8.00 | Full Range 2.0 to 20.0 | score on a scale |
| Change From Baseline Score in the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Motor Function Scale at Month 12 | >/=4 SMN2 Copies, Risdiplam | Change from Baseline at Month 12 | 16.00 | Full Range 8.0 to 19.0 | score on a scale |
| Percentage of Participants Who Achieve a Score of 40 or Higher, 50 or Higher, and 60 or Higher in the CHOP INTEND Motor Function Scale at Month 12 | 2 SMN2 Copies, Risdiplam | Score >=40 | 75.0 | 90% Confidence Interval 40.03 to 95.36 | percentage of participants |
| Percentage of Participants Who Achieve a Score of 40 or Higher, 50 or Higher, and 60 or Higher in the CHOP INTEND Motor Function Scale at Month 12 | 3 SMN2 Copies, Risdiplam | Score >=40 | 100 | 90% Confidence Interval 79.42 to 100.00 | percentage of participants |
| Percentage of Participants Who Achieve a Score of 40 or Higher, 50 or Higher, and 60 or Higher in the CHOP INTEND Motor Function Scale at Month 12 | >/=4 SMN2 Copies, Risdiplam | Score >=40 | 100 | 90% Confidence Interval 47.29 to 100.00 | percentage of participants |
| Percentage of Participants Who Achieve a Score of 40 or Higher, 50 or Higher, and 60 or Higher in the CHOP INTEND Motor Function Scale at Month 12 | 2 SMN2 Copies, Risdiplam | Score >=50 | 75.0 | 90% Confidence Interval 40.03 to 95.36 | percentage of participants |
| Percentage of Participants Who Achieve a Score of 40 or Higher, 50 or Higher, and 60 or Higher in the CHOP INTEND Motor Function Scale at Month 12 | 3 SMN2 Copies, Risdiplam | Score >=50 | 100 | 90% Confidence Interval 79.42 to 100.00 | percentage of participants |
| Percentage of Participants Who Achieve a Score of 40 or Higher, 50 or Higher, and 60 or Higher in the CHOP INTEND Motor Function Scale at Month 12 | >/=4 SMN2 Copies, Risdiplam | Score >=50 | 100 | 90% Confidence Interval 47.29 to 100.00 | percentage of participants |
| Percentage of Participants Who Achieve a Score of 40 or Higher, 50 or Higher, and 60 or Higher in the CHOP INTEND Motor Function Scale at Month 12 | 2 SMN2 Copies, Risdiplam | Score >=60 | 37.5 | 90% Confidence Interval 11.11 to 71.08 | percentage of participants |
| Percentage of Participants Who Achieve a Score of 40 or Higher, 50 or Higher, and 60 or Higher in the CHOP INTEND Motor Function Scale at Month 12 | 3 SMN2 Copies, Risdiplam | Score >=60 | 100 | 90% Confidence Interval 79.42 to 100.00 | percentage of participants |
| Percentage of Participants Who Achieve a Score of 40 or Higher, 50 or Higher, and 60 or Higher in the CHOP INTEND Motor Function Scale at Month 12 | >/=4 SMN2 Copies, Risdiplam | Score >=60 | 100 | 90% Confidence Interval 47.29 to 100.00 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03779334/results